The Netherlands' cannabis pilot is showing early improvements in regulated supply and track and trace systems, but packaging, potency guidance, hash availability, and consumer information still need work. The experiment offers a rare look at what happens when an established tolerated retail market attempts to convert its entire supply chain into a regulated system.

The United States has one of the world's largest cannabis markets but remains a minor participant in international medical cannabis trade. Federal medical rescheduling could create new opportunities, but U.S. operators still face established foreign competitors, pharmaceutical quality standards, permitting requirements, logistics costs, and growing domestic production in importing markets.

Canada remains the world's largest medical cannabis exporter, but growing European production is beginning to challenge its lead. Germany's expanding market, Portugal's rapid export growth, stricter pharmaceutical standards, reimbursement changes, and new lower cost suppliers are reshaping international cannabis competition.

Canada still supplies most of Australia's imported medical cannabis, but Thailand rapidly gained market share in 2025 while Australian domestic production reached a new high. The shift shows an increasingly competitive supply chain where pricing, quality standards, contracts, inventory, and reliable international market access matter more.

Curaleaf is pursuing a proposed $272 million takeover of Aurora Cannabis as major operators search for greater international scale, medical market access, and operating efficiency. The proposal shows how cannabis consolidation is shifting toward strategic assets, global distribution, capital efficiency, and long term competitive positioning.

A new GCNC and Whitney Economics report examines how pricing compression is reshaping cannabis markets across North America, Europe, Latin America, and Israel. The bigger lesson is that emerging markets can look attractive early, but operators and investors need to model margin pressure before supply expands and prices fall.

Organigram is using Germany as its first real step into broader European medical cannabis growth. The bigger lesson for operators is that international expansion still depends on local compliance, strong distribution partners, and the patience to build market by market.